by Amy Berger | Aug 6, 2020 | Blog, News
Ferret infection model: Since early in the pandemic, IITRI has been working on developing new animal models to test out therapeutics and treatments for COVID-19 (in addition to in vitro offerings of efficacy assays, neutralization assays, and surface decontaminant...
by Amy Berger | Aug 5, 2020 | Blog, News
IITRI is proud to share the promising news of one of our partners, Moleculin! Our team here at IITRI was contracted to perform additional in vitro testing of their drug candidate (WP1122) for antiviral effects against SARS-CoV-2. We used growth medium that more...
by Amy Berger | Jul 13, 2020 | Blog, News
IITRI now offers an improved bleomycin (BLM) induced pulmonary fibrosis mouse model that can recapitulate many of the complex profibrotic responses that are also observed in the lungs of those suffering from idiopathic pulmonary fibrosis (IPF) and perhaps COVID-19...
by Amy Berger | Mar 19, 2020 | Blog, News
IITRI is now in custody of the a SARS-CoV-2 strain responsible for COVID-19. Our team is working on characterizing the strain for in vitro studies and in vivo modeling to test current vaccines and antivirals in addition to developing new treatments for this...
by iitri | Apr 12, 2019 | News
David McCormick has been selected to present on the development of novel agents to treat sleep-disordered breathing (SDB; sleep apnea) at the invitation-only Science2Startup (S2S)™ symposium on April 23, 2019, in Cambridge. The presenting group of 12 was...
by iitri | Aug 21, 2018 | News
IITRI-Vaccine-Antiinfectives-Lunch-n-Learn Title: Regulatory Approval Pathways for Vaccines and Antivirals: Laying the Groundwork Location: MassBio, 300 Technology Square, 8th Floor, Cambridge MA, 02139 Date/Time: Tuesday, September 25, 2018 Registration: 11 am...
Recent Comments